Closing the gap between evidence and practice in chronic kidney disease

Meg Jardine, Bertram Kasiske, Dwomoa Adu, Mona Alrukhaimi, Gloria Ashuntantang, Shakti Basnet, Worawon Chailimpamontree, Jonathan Craig, Donal O'Donoghue, Vlado Perkovic, Neil Powe, Charlotte Roberts, Yusuke Suzuki, Tetsuhiro Tanaka, Katrin Uhlig

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There are major gaps between our growing knowledge of effective treatments for chronic kidney disease (CKD), and the delivery of evidence-based therapies to populations around the world. Although there remains a need for new, effective therapies, current evidence suggests that many patients with CKD are yet to fully realize the benefits of blood pressure–lowering drugs (with and without reducing proteinuria with renin-angiotensin system blockade), wider use of statins to reduce atherosclerotic cardiovascular disease events, and better glycemic control in both type 1 and type 2 diabetes. There are many barriers to optimizing evidence-based nephrology care around the world, including access to health care, affordability of treatments, consumer attitudes and circumstances, the dissemination of appropriate knowledge, the availability of expertise and structural impediments in the delivery of health care. Further investment in implementation science that addresses the major barriers to effective care in a cost-effective manner could yield both local and global benefits.

Original languageEnglish
Pages (from-to)114-121
Number of pages8
JournalKidney International Supplements
Volume7
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Closing the gap between evidence and practice in chronic kidney disease'. Together they form a unique fingerprint.

Cite this